Cited by 37Substance Abuse Treatment and OutcomesNeuroscience and Neuropharmacology ResearchPharmacogenetics and Drug Metabolism

The natural history of tolerance to the benzodiazepines

Higgitt, A., Fonagy, P., Lader, M.·1988·Psychological Medicine. Monograph Supplement

Abstract

Dependence on benzodiazepines following continued use is by now a well-documented clinical phenomenon. Benzodiazepines differ in their dependence potential. The present studies were aimed at examining the possibility that differential rates of tolerance development might account for differences in dependence risk. Four studies are reported. The first three studies concerned normal subjects. The development of tolerance over a fifteen day period was demonstrated for three different benzodiazepines (ketazolam, lorazepam and triazolam) using two paradigms. Tolerance in terms of a reduction in effectiveness of a repeated given dose was most notable for the benzodiazepine with a medium elimination half-life (lorazepam) for physiological, behavioural and subjective measures. In the case of the drug with the longest elimination half-life (ketazolam) reduction in effectiveness could only be assumed to be occurring if account was taken of the steady increase in plasma concentrations of active metabolites. For this drug it seemed that the physiological measures were those most likely to demonstrate the development of tolerance. Although triazolam showed few significant drug effects on this paradigm (testing being 12 hours after ingestion of this short half-life benzodiazepine), tolerance was seen to develop on some subjective measures. Using an alternative method of testing tolerance, assessing responses to a diazepam challenge dose, a high degree of tolerance on two-thirds of the measures was observed in subjects when pretreated with the benzodiazepine with the most marked accumulation of active metabolites (ketazolam). The other two drugs also led to tolerance development on a range of measures; this was more marked for lorazepam than triazolam. Blunting of the growth hormone response to diazepam was the most sensitive and reliable method of detecting tolerance to the benzodiazepines. Symptoms on discontinuation of the two weeks' intake of the benzodiazepines were marked for all the drugs but unrelated to either the tolerance induced or the elimination half-life of the particular drug. A further clinical study revealed that tolerance persisted in a group of long-term benzodiazepine users for between four months and two years following complete abstinence from the drug. These patients appeared to be less affected by diazepam in terms of its commonly observed subjective effects, regardless of their original medication. These ex-long-term users of benzodiazepines were, however, more likely to manifest two specific types of effects--immediate 'symptom' reduction and exacerbation of 'withdrawal symptoms' over the subsequent week.(ABSTRACT TRUNCATED AT 400 WORDS)

Integrity signals

Registry

Crossref · 10.1017/s0264180100000412

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In Higgitt 1988, former benzodiazepine patients had higher levels than controls of drowsiness, muscle cramps, impaired concentrations, eye soreness, and sadness.

    “Former BZD patients had higher levels than controls of: drowsiness, muscle cramps, impaired concentrations, eye soreness, and sadness”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Higgitt, A., Fonagy, P., & Lader, M.
Affiliations
St Mary's Hospital (GB)
Venue
Psychological Medicine. Monograph Supplement
Published
1988
Volume
13
Pages
1-55
ISSN
  • 0264-1801 (ISSN-L)
  • 2051-2023
OpenAlex
W2120166535
Cited by
37
References
12
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 1 · 2014: 1 · 2012: 3
FWCI
3.19
Type
journal article
Language
en
Open access
closed
Locations
  • Psychological Medicine Monograph Supplement (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
benzodiazepine dependence, lorazepam, triazolam, elimination half-life, bioactive metabolites, growth hormone response, withdrawal symptoms
MeSH terms
Adult, Affect, Arousal, Attention, Diazepam, Dose-Response Relationship, Drug, Drug Tolerance, Electroencephalography, Female, Humans, Long-Term Care, Male, Metabolic Clearance Rate, Risk Factors, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review